Management Team

ImmunOs Therapeutics´ team has extensive expertise in the field of drug development and global commercialization in immunology, immunotherapy, and oncology.

The Company´s mission is to develop the next generation of novel immunotherapeutics that will improve the lives of patients with serious diseases.

REINHARD AMBROS, PHD

CHIEF EXECUTIVE OFFICER

Dr. Reinhard Ambros has held international leadership positions in venture capital, corporate strategy, BD&L and pharmaceutical product development. From 2005 through 2017, Reinhard developed and led the Novartis Venture Fund to become one of the largest corporate biotechnology venture funds in the life sciences industry. Previously, he served as head of group strategic planning and BD&L for cardiovascular and metabolic diseases for Novartis Corporation and Novartis Pharma AG, respectively. Reinhard serves on the boards of public and private biotechnology companies in Europe and the United States, and as an advisor to German and Swiss Government Biotechnology Funds.

HILMAR EBERSBACH, PHD

CHIEF SCIENTIFIC OFFICER

Hilmar Ebersbach has been Vice President for Antibody Development and Protein Engineering at ImmunOs since Oct 2022. He has more than 20 years of experience in research and development of biologics including 15 years at Novartis/NIBR in different roles with increasing responsibilities in scientific and operational leadership. Hilmar has expertise in the development of a broad range of modalities, including therapeutic and multi-specific proteins, bio-conjugates, and CAR-T and AAV based assets, and has advanced a number of therapeutic candidates from early research into clinical development in the fields immuno-oncology and autoimmune disease. Hilmar has contributed to numerous scientific publications and granted patents, completed post-doctoral training in the Plückthun lab at University of Zurich, and holds a PhD in protein engineering and a diploma in biochemistry, both from University of Halle, Germany.

STEVE COATS, PHD

CHIEF DEVELOPMENT OFFICER

Steve Coats has been Chief Development Officer of ImmunOs since December 2021. He has over 25 years of experience as a biopharmaceutical research and development executive, leading non-clinical, clinical and technology teams to develop innovative biologic-based therapies using multiple technology platforms in a variety of therapeutic areas. Steve spent over 15 years at AstraZeneca/MedImmune, most recently serving as VP of R&D, where he led global project teams developing novel biologic therapies through IND/CTA filings and proof of concept phase 2 clinical trials. Prior to AstraZeneca, Steve was a research director at Amgen where he led research and discovery teams for both small molecules as well as biologic therapies. Steve completed post-doctoral training at the Fred Hutchinson Cancer Research Center in Seattle with a focus on signal transduction and the cell cycle. He holds a Ph.D. in molecular and cell biology from Vanderbilt University and a B.A. from the University of New Hampshire. 

CHRISTOPH RENNER, MD

CHIEF MEDICAL OFFICER & CO-FOUNDER

Prof. Dr. Christoph Renner is a Professor of Medical Oncology at the University of Basel. Previous appointments include Head of the Department of Internal Medicine and Oncology, Head of the Cancer Center, Head of the division of Clinical Immunology and Professor for Clinical and Experimental Oncology at the University of Zurich. Christoph joined the Swiss Tumor Institute in January 2013 and started a Cancer Center Initiative Network. He has a strong background in antibody engineering and has been an affiliate of the Ludwig Institute for Cancer Research for more than 15 years and a senior physician specialist in oncology, onco-immunology and internal medicine at Hirslanden Hospital Zurich. Prof. Dr. Renner is a member of different research organizations and has served on the board of the Swiss Group for Clinical Cancer Research for six years. 

CLAUDIA BERGER, MPHARM

CHIEF CLINICAL OPERATIONAL OFFICER

Claudia Berger is a proven expert in the field of clinical development and has been focusing on clinical trial operations and project management for more than 15 years. Before joining ImmunOs Therapeutics, she served as Director Clinical Operations at Inflazome Ltd, an Irish company recently acquired by Roche. Prior to that, she headed clinical operations at several biopharmaceutical companies such as Kinarus AG and Delenex Therapeutics, leading Phase I/II clinical programs, including profiling, biomarker and proof-of-concept studies with both biologics and small molecules and establishing quality assurance systems. From 2007 to 2012, she held several positions of increasing responsibility at the Novartis Institute for Biomedical Research (NIBR), most recently as Principal Clinical Scientist. Claudia Berger holds a Master of Science Degree in Pharmacy and a Diploma as a University Professional of Advanced Studies in Pharmaceutical Medicine.

CONSTANZE GUENTHER, PHD

CHIEF TECHNICAL OFFICER

Constanze Guenther has been Senior Vice President, CMC and Technical Development of ImmunOs since August 2023. Constanze has more than 20 years of experience in technical development and operations of biologics, including 13 years at Novartis in different roles with increasing responsibilities in technical and operational leadership. She has expertise in the development and manufacturing of a broad range of modalities, including antibodies, therapeutic proteins, bio-conjugates, and CAR-T assets, and has advanced several therapeutic candidates through clinical development to commercial launch. Constanze received an executive MBA from HSG (St. Gallen, Switzerland), and holds a PhD in protein biotechnology and a diploma in biology, both from University of Halle, Germany.